George V. Pérez

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945

J. Wiśniewski, Osmany Guirola, Y. Perera, 2021, bioRxiv.

Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

Y. Perera, G. Guillén, Ariadna Garcia, 2020, medRxiv.

CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 Inhibition

J. Wiśniewski, Y. Perera, V. Besada, 2022, Frontiers in Molecular Biosciences.

Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300

J. Wiśniewski, Y. Perera, V. Besada, 2021, bioRxiv.

CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model

Y. Perera, V. Besada, L. González, 2022, Biomedicines.

Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines

Y. Perera, Ailyn C. Ramón, S. Perea, 2023, BMC Genomics.

Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection

Y. Perera, Y. Ramos, Ailyn C. Ramón, 2021, bioRxiv.

Gene Expression Profiling Unveils the Temporal Dynamics of CIGB-300-Regulated Transcriptome in AML Cells

Y. Perera, Ailyn C. Ramón, S. Perea, 2023, bioRxiv.